Therapeutic Nuclear Drug Market Report 2026

Therapeutic Nuclear Drug Market Overview

• Therapeutic Nuclear Drug market size has reached to $2.19 billion in 2025 • Expected to grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Increasing Prevalence Of Cancer Is Driving The Growth Of The Therapeutic Nuclear Drug Market • Market Trend: Advancements Driving Expansion Of Targeted Radiotherapies • North America was the largest region in 2025.

What Is Covered Under Therapeutic Nuclear Drug Market?

Therapeutic nuclear drugs refer to a type of medication that uses radioactive materials to target and treat diseases, particularly cancer. These drugs utilize targeted radiopharmaceuticals that bind to cancer cells, delivering a therapeutic dose of radiation directly to these cells to destroy them while minimizing damage to surrounding healthy tissue. The main types of therapeutic nuclear drug are radium-223, lutetium-177, iodine-131, others. Radium-223 is a type of therapeutic nuclear drug used primarily to treat prostate cancer that has spread to the bones. These are distributed through various distribution channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are used in various applications such as thyroid, bone metastasis, lymphoma, and others.

What Is The Therapeutic Nuclear Drug Market Growth Forecast?

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to development of novel therapeutic isotopes, expansion of precision oncology approaches, increasing investment in nuclear medicine infrastructure, growing clinical trials for radioligand therapies, favorable regulatory approvals for targeted nuclear drugs. Major trends in the forecast period include rising adoption of targeted radiopharmaceutical therapies, increasing use of lutetium-177 and alpha-emitting isotopes, growth in cancer-specific nuclear drug applications, expansion of combination therapies with nuclear drugs, strengthening focus on safety dosimetry and regulatory compliance.

Global Therapeutic Nuclear Drug Market Segmentation

1) By Type: Radium-223, Lutetium-177, Iodine-131, Other Types 2) By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes 3) By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications

What Is The Driver Of The Therapeutic Nuclear Drug Market?

The increasing prevalence of cancer is expected to propel the growth of the therapeutic nuclear drug market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells. The prevalence of cancer is due to improved detection and diagnosis, lifestyle factors, environmental exposures, and genetic factors. Therapeutic nuclear drugs act as a valuable component in the arsenal against cancer, providing targeted and effective treatment options for patients by reducing tumor size, alleviating symptoms, and improving quality of life. For instance, in February 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, It is projected that over 35 million new cancer cases will arise by 2050, marking a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the therapeutic nuclear drug industry.

Key Players In The Global Therapeutic Nuclear Drug Market

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

Global Therapeutic Nuclear Drug Market Trends and Insights

Major companies operating in the therapeutic nuclear drug market are advancing targeted radiotherapies by showcasing novel multi-tumor treatment potential through emerging clinical data. These efforts aim to strengthen innovation pipelines, expand therapeutic applications, and accelerate adoption of next-generation radiopharmaceuticals. For instance, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, launched a new data for ATNM-400, its first-in-class Actinium-225 radiotherapy, demonstrating multi-tumor potential including in non-small cell lung cancer (NSCLC). The findings were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is designed to deliver highly potent alpha-particle therapy with precision targeting, supporting its potential as a transformative therapeutic platform across multiple solid tumors. This advancement highlights the industry’s focus on expanding clinical applications of actinium-based radiotherapies to improve patient outcomes and broaden market opportunities.

What Are Latest Mergers And Acquisitions In The Therapeutic Nuclear Drug Market?

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aims to enhance its therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences is a US-based biotechnology company focused on developing next-generation nuclear therapeutic medicines.

Regional Insights

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Therapeutic Nuclear Drug Market?

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Therapeutic Nuclear Drug Market Report 2026?

The therapeutic nuclear drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic nuclear drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.